Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.7966 USD
−30.54 M USD
675.00 K USD
87.47 M
About Unicycive Therapeutics, Inc.
Sector
Industry
CEO
Shalabh Gupta
Website
Headquarters
Los Altos
Founded
2016
FIGI
BBG01163JG34
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of UNCY is 0.8111 USD — it has increased by 1.24% in the past 24 hours. Watch Unicycive Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Unicycive Therapeutics, Inc. stocks are traded under the ticker UNCY.
UNCY stock has risen by 11.06% compared to the previous week, the month change is a 30.08% rise, over the last year Unicycive Therapeutics, Inc. has showed a −8.87% decrease.
We've gathered analysts' opinions on Unicycive Therapeutics, Inc. future price: according to them, UNCY price has a max estimate of 10.00 USD and a min estimate of 2.00 USD. Watch UNCY chart and read a more detailed Unicycive Therapeutics, Inc. stock forecast: see what analysts think of Unicycive Therapeutics, Inc. and suggest that you do with its stocks.
UNCY reached its all-time high on Jul 13, 2021 with the price of 8.7300 USD, and its all-time low was 0.2020 USD and was reached on Aug 13, 2024. View more price dynamics on UNCY chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
UNCY stock is 6.78% volatile and has beta coefficient of 2.04. Track Unicycive Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Unicycive Therapeutics, Inc. there?
Today Unicycive Therapeutics, Inc. has the market capitalization of 83.00 M, it has increased by 1.85% over the last week.
Yes, you can track Unicycive Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Unicycive Therapeutics, Inc. is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
UNCY earnings for the last quarter are −0.05 USD per share, whereas the estimation was −0.15 USD resulting in a 67.59% surprise. The estimated earnings for the next quarter are −0.09 USD per share. See more details about Unicycive Therapeutics, Inc. earnings.
Unicycive Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
UNCY net income for the last quarter is −4.10 M USD, while the quarter before that showed 3.93 M USD of net income which accounts for −204.22% change. Track more Unicycive Therapeutics, Inc. financial stats to get the full picture.
No, UNCY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 14.00 employees. See our rating of the largest employees — is Unicycive Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Unicycive Therapeutics, Inc. EBITDA is −28.68 M USD, and current EBITDA margin is −3.04 K%. See more stats in Unicycive Therapeutics, Inc. financial statements.
Like other stocks, UNCY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Unicycive Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Unicycive Therapeutics, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Unicycive Therapeutics, Inc. stock shows the neutral signal. See more of Unicycive Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.